GlassScriptPhysician profile
Kiersten Prince
NPI 1467689174
$1,041.72
in general payments reported to CMS, 2019-2025
21 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2022: $107 · 2023: $220 · 2024: $133 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $164.93 | 2022-2025 | Apligraf, Affinity, Puraply |
| Smith+Nephew, INC. | $151.94 | 2022-2025 | Grafix Pl, Collagenase Santyl |
| Kerecis Limited | $95.74 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Next Science LLC | $83.89 | 2023 | Blastx, Xperience, Surgx |
| Urgo Medical North America, LLC | $74.20 | 2023-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgoclean Ag |
| Novo Nordisk INC | $57.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.16 | 2019 | |
| Boston Scientific Corporation | $53.86 | 2023-2024 | Bionic Navigator |
| Integra Lifesciences Corporation | $46.00 | 2022-2025 | Tcc-Ez |
| Paratek Pharmaceuticals, INC. | $45.69 | 2025 | Nuzyra |
| Solventum Corporation | $34.21 | 2025 | Activ.A.C., Promogran Prisma |
| Triad Life Sciences INC. | $26.66 | 2022 | |
| Merck Sharp & Dohme LLC | $26.20 | 2019 | |
| Astellas Pharma US INC | $24.64 | 2019 | |
| Abbvie INC. | $21.56 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $15.23 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.95 | 2019 | |
| Pfizer INC. | $13.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2019 | |
| Amarin Pharma, INC. | $12.84 | 2019 | |
| Lilly USA, LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiersten Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.